Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.605 USD | -2.57% |
|
-8.50% | -47.53% |
06-21 | Factbox-European companies cut jobs as economy sputters | RE |
06-19 | Global markets live: Vodafone, Bayer, Apple, Microsoft, Qualcomm... | ![]() |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-47.53% | 3.61B | - | ||
+18.73% | 67.97B | A- | ||
-6.80% | 45.92B | A- | ||
+23.48% | 43.74B | B+ | ||
+32.85% | 28.16B | A- | ||
+8.59% | 19.17B | C+ | ||
-15.00% | 14.73B | B+ | ||
-25.07% | 14.52B | A- | ||
-32.00% | 11.64B | A- | ||
-33.52% | 11.23B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UMI Stock
- UMICY Stock
- Ratings Umicore SA